FDA nano-teams with academia
This article was originally published in The Tan Sheet
Executive Summary
FDA collaborates with the Alliance for NanoHealth to hasten development of novel medical products using nanotechnology. The FDA/ANH Nanotechnology Initiative aims to expand understanding of how nanoparticles affect biologic systems and develop processes to potentially mitigate nano-related risks, all of which will be placed in the public domain. FDA March 10 said the collaboration is part of its Critical Path initiative for biomarker validation, better clinical trial design and new manufacturing methods (1"The Tan Sheet" Oct. 3, 2005, p. 7)
You may also be interested in...
Von Eschenbach Likely To Put FDA Critical Path Initiative Back On Track
The appointment of National Cancer Institute Director Andrew von Eschenbach to FDA acting commissioner is likely to revitalize the agency's stalled Critical Path initiative
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.